1 month Chardan Capital Lowers Editas Medicine (NASDAQ:EDIT) Price Target to $12.00MarketBeat
Chardan Capital reduced their price target on shares of Editas Medicine from $20.00 to $12.00 and set a “buy” rating for the company in a research report on Tuesday.
X